Los Angeles, CANCT04224558Now EnrollingIRB Ready

Crohn Disease Clinical Trial in Los Angeles, CA

Access cutting-edge crohn disease treatment through this phase 1/2 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Cedars-Sinai Medical Center

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access crohn disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related crohn disease treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this crohn disease clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Crohn Disease Study in Los Angeles

Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called "high dose immunoablation" followed by autologous hematopoietic stem cell transplantation (HSCT). This study removes over active lymphocytes (immunoablation) and replaces them using blood stem cells that have been taken from the patient's own body. The aim of the study is to reset or reprogram the patient's immune system to its state prior to diagnosis.

Sponsor: Cedars-Sinai Medical Center

Who Can Participate

Inclusion Criteria

Aged 13-28 years are eligible
Confirmed diagnosis of active Crohn's disease:
Diagnosis of Crohn's disease based on typical radiological appearances and / or typical histology at least 6 months prior to screening.
Active disease at the time of registration to the trial, defined as i) PCDAI \> 30, and ii) Two of the following:
elevated CRP
endoscopic evidence of active disease confirmed by histology
clear evidence of active small bowel Crohn's disease on CT or MR enterography.
Unsatisfactory course despite 3 immunosuppressive agents (usually azathioprine, methotrexate and infliximab, adalimumab and/or certolizumab) in addition to corticosteroids. Patients should have relapsing disease (i.e. 1 exacerbation/year) despite thiopurines, methotrexate and/or infliximab/adalimumab/certolizumab maintenance therapy or clear demonstration of intolerance / toxicity to these drugs.
Current problems unsuitable for surgery or patient at risk for developing short bowel syndrome.
Accepted by a majority of the members of the combined IBD Center as an appropriate candidate (see Selection description below).
Informed consent
Prepared to undergo additional study procedures as per trial schedule
Patient has undergone intensive counseling about risks

Exclusion Criteria

Pregnancy or unwillingness to use adequate contraception during the study, in women of childbearing age. Unwillingness of using appropriate contraceptive measures in males.
Concomitant severe disease
renal: creatinine clearance \< 30 mL/min (measured or estimated)
cardiac: clinical evidence of refractory congestive heart failure; left ventricular ejection fraction \< 40% by cardiac echo; chronic atrial fibrillation necessitating oral anticoagulation; uncontrolled ventricular arrhythmia; pericardial effusion with hemodynamic consequences as evaluated by an experienced echo cardiographer
pulmonary: diffusion capacity \<40%
psychiatric disorders including active drug or alcohol abuse
concurrent or recent history of malignant disease (excluding non-melanoma skin cancer)
uncontrolled hypertension, defined as resting systolic blood pressure ≥ 140 and/or resting diastolic pressure ≥ 90 despite at least 2 anti-hypertensive agents.
any infection with HIV, HTLV-1 or 2, hepatitis viruses, or any other infection the investigators consider a contraindication to participation.
other chronic disease causing significant organ failure.
Infection or risk thereof:
Current clinical relevant abscess or significant active infection.
Perianal fistula without free drainage. Perianal fistulas is not an exclusion provided there is natural free drainage or a seton suture(s) have been placed.
History of tuberculosis or at current increased risk of tuberculosis
Quantiferon Gold test result or other investigations that the investigators regard as evidence of active tuberculosis.
Abnormal chest X-ray (CXR) consistent with active infection or neoplasm. 6\) Significant malnutrition: Body Mass Index (BMI) ≤ 18, serum albumin \< 20 g/l. 7\) Previous poor compliance. 8) Concurrent enrollment in any other protocol using an investigational drug or hematopoietic growth factor up to four weeks before study entry.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT04224558) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Crohn Disease Treatment Options in Los Angeles, CA

If you're searching for crohn disease treatment options in Los Angeles, CA, this clinical trial (NCT04224558) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced crohn disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all crohn disease clinical trials near you to find additional studies recruiting in your area.

More Crohns Disease Trials in Los Angeles, CA

See all crohns disease clinical trials recruiting in Los Angeles — not just this study.

Browse Crohns Disease Trials in Los Angeles →

Browse More Trials by Condition

Crohns Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA